Search Result

Results for "

half-life

" in MedChemExpress (MCE) Product Catalog:

By Targets:	5-HT Receptor (1) ADAMTS (1) Adrenergic Receptor (2) Akt (2) Angiotensin-converting Enzyme (ACE) (1) Antibiotic (4) Antifolate (1) Apelin Receptor (APJ) (1) Apoptosis (1) Bacterial (4) c-Myc (1) Calcium Channel (1) CD3 (3) CFTR (1) DNA-PK (2) DNA/RNA Synthesis (3) Dopamine Receptor (1) Drug Metabolite (4) Drug-Linker Conjugates for ADC (1) Endogenous Metabolite (4) Factor Xa (1) FGFR (1) Fluorescent Dye (1) GABA Receptor (1) GCGR (1) HBV (1) HCV (2) HCV Protease (2) HDAC (1) HIV Protease (1) IFNAR (1) Isotope-Labeled Compounds (2) JAK (1) JNK (1) Keap1-Nrf2 (1) LPL Receptor (1) MDM-2/p53 (1) MMP (1) Orexin Receptor (OX Receptor) (1) Orthopoxvirus (1) Parasite (2) Phosphatase (1) PI3K (2) Potassium Channel (1) Prostaglandin Receptor (3) Proton Pump (1) RSV (1) SARS-CoV (7) Sodium Channel (1) Virus Protease (1) YAP (3) γ-secretase (2)
By Research Areas:	Cancer (21) Cardiovascular Disease (8) Endocrinology (7) Infection (17) Inflammation/Immunology (15) Metabolic Disease (4) Neurological Disease (8)

By Targets:

5-HT Receptor (1)

ADAMTS (1)

Adrenergic Receptor (2)

Akt (2)

Angiotensin-converting Enzyme (ACE) (1)

Antibiotic (4)

Antifolate (1)

Apelin Receptor (APJ) (1)

Apoptosis (1)

Bacterial (4)

c-Myc (1)

Calcium Channel (1)

CD3 (3)

CFTR (1)

DNA-PK (2)

DNA/RNA Synthesis (3)

Dopamine Receptor (1)

Drug Metabolite (4)

Drug-Linker Conjugates for ADC (1)

Endogenous Metabolite (4)

Factor Xa (1)

FGFR (1)

Fluorescent Dye (1)

GABA Receptor (1)

GCGR (1)

HBV (1)

HCV (2)

HCV Protease (2)

HDAC (1)

HIV Protease (1)

IFNAR (1)

Isotope-Labeled Compounds (2)

JAK (1)

JNK (1)

Keap1-Nrf2 (1)

LPL Receptor (1)

MDM-2/p53 (1)

MMP (1)

Orexin Receptor (OX Receptor) (1)

Orthopoxvirus (1)

Parasite (2)

Phosphatase (1)

PI3K (2)

Potassium Channel (1)

Prostaglandin Receptor (3)

Proton Pump (1)

RSV (1)

SARS-CoV (7)

Sodium Channel (1)

Virus Protease (1)

YAP (3)

γ-secretase (2)

By Research Areas:

Cancer (21)

Cardiovascular Disease (8)

Endocrinology (7)

Infection (17)

Inflammation/Immunology (15)

Metabolic Disease (4)

Neurological Disease (8)

Inhibitors & Agonists

Fluorescent Dye

Peptides

Inhibitory Antibodies

Natural
Products

Isotope-Labeled Compounds

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-134636

PAPA NONOate	Endogenous Metabolite	Endocrinology
PAPA NONOate is a NO donor with a NO release half-life of 77 min (22-25°C). PAPA NONOate may represent a potential research for impaired wound healing in diabetes by increasing the rate of collagen synthesis at the wound site .

HY-13859

Clevudine L-FMAU	HBV DNA/RNA Synthesis Orthopoxvirus	Infection
Clevudine (L-FMAU), a nucleoside analog of the unnatural L-configuration, has potent anti-HBV activity with long half-life, low toxicity. Clevudine is a non-competitive inhibitor that is not incorporated into the viral DNA but rather binds to the polymerase. Clevudine is active against cowpox virus respiratory infection in mice .

HY-121243

Halauxifen

Others Others

Halauxifen is a herbicide with plasma elimination half-life of 1 h .
HY-P99478

Bifarcept

IFNAR Inflammation/Immunology

Bifarcept is a recombinant antibody of interferon receptor type I (IFN-RI). Bifarcept can bind IFN-β and prolong its serum half-life .
HY-120374

V-PYRRO/NO

Others Metabolic Disease

V-PYRRO/NO is a NO donor in vivo. Following hepatic metabolism, it spontaneously decomposes with a half-life of 3 seconds to liberate NO.

Halauxifen	Others	Others
Halauxifen is a herbicide with plasma elimination half-life of 1 h .

Bifarcept	IFNAR	Inflammation/Immunology
Bifarcept is a recombinant antibody of interferon receptor type I (IFN-RI). Bifarcept can bind IFN-β and prolong its serum half-life .

V-PYRRO/NO	Others	Metabolic Disease
V-PYRRO/NO is a NO donor in vivo. Following hepatic metabolism, it spontaneously decomposes with a half-life of 3 seconds to liberate NO.

HY-144771

SARS-CoV-2-IN-14	SARS-CoV	Infection
SARS-CoV-2-IN-14 (compound 6) is a potent inhibitor of SARS-CoV-2 with an IC₅₀ of 0.39 μM. SARS-CoV-2-IN-14 is a niclosamide analogue. SARS-CoV-2-IN-14 contains higher stability in human plasma and liver S9 enzymes assay than niclosamide, which can improve bioavailability and half-life when administered orally .

HY-144772

SARS-CoV-2-IN-15	SARS-CoV	Infection
SARS-CoV-2-IN-15 (compound 11) is a potent inhibitor of SARS-CoV-2 with an IC₅₀ of 0.49 μM. SARS-CoV-2-IN-15 is a niclosamide analogue. SARS-CoV-2-IN-15 contains higher stability in human plasma and liver S9 enzymes assay than niclosamide, which can improve bioavailability and half-life when administered orally .

HY-144770

SARS-CoV-2-IN-13	SARS-CoV	Infection
SARS-CoV-2-IN-13 (compound 5) is a potent inhibitor of SARS-CoV-2 with an IC₅₀ of 0.057 μM. SARS-CoV-2-IN-13 is a niclosamide analogue. SARS-CoV-2-IN-13 contains higher stability in human plasma and liver S9 enzymes assay than niclosamide, which can improve bioavailability and half-life when administered orally .

HY-158395

TEAD-IN-13

YAP Cancer

TEAD-IN-13 (64) is an orally active TEAD inhibitor, with an IC₅₀ of <100 nM and a half-life of 3.2 h in mouse .
HY-158396

TEAD-IN-14

YAP Cancer

TEAD-IN-14 (75a) is an orally active TEAD inhibitor, with an IC₅₀ of <100 nM and a half-life of 2.3 h in mouse .
HY-158394

TEAD-IN-12

YAP Cancer

TEAD-IN-12 (58B) is an orally active TEAD inhibitor, with an IC₅₀ of <100 nM and a half-life of 3.6 h in mouse .

TEAD-IN-13	YAP	Cancer
TEAD-IN-13 (64) is an orally active TEAD inhibitor, with an IC₅₀ of <100 nM and a half-life of 3.2 h in mouse .

TEAD-IN-14	YAP	Cancer
TEAD-IN-14 (75a) is an orally active TEAD inhibitor, with an IC₅₀ of <100 nM and a half-life of 2.3 h in mouse .

TEAD-IN-12	YAP	Cancer
TEAD-IN-12 (58B) is an orally active TEAD inhibitor, with an IC₅₀ of <100 nM and a half-life of 3.6 h in mouse .

HY-163683

EB-PSMA-617	Drug-Linker Conjugates for ADC	Cancer
EB-PSMA-617 is a modified form of PSMA-617 that has enhanced pharmacokinetic properties by conjugating it to Evans Blue (EB) to extend its circulation half-life to improve prostate tumor uptake and radiotherapy efficacy. In preclinical studies using PC3-PIP-loaded mice, EB-PSMA-617 demonstrated prolonged blood half-life, increased accumulation in PSMA-positive tumors, and successful tumor elimination with lower radioactivity .

HY-10758

FXa-IN-1	Factor Xa	Cardiovascular Disease
FXa-IN-1 is a FXa inhibitor (IC₅₀: 3 nM, K_i: 0.7 nM) with respectable oral bioavailability and half-life in vivo. FXa-IN-1 can be used for thromboembolic disorders .

HY-103501

SB-205384	GABA Receptor	Neurological Disease
SB-205384 is a GABAA receptor modulator. The primary effect of SB-205384 on GABAA-activated currents is a prolonged response decay half-life upon removal of the agonist .

HY-145362

S1P1 agonist 4

LPL Receptor Others

S1P1 agonist 4 has a better profile in both potency (EC₅₀ < 0.05 mg/kg) and predicted human half-life (t1/2 ∼ 5 days).

S1P1 agonist 4	LPL Receptor	Others
S1P1 agonist 4 has a better profile in both potency (EC₅₀ < 0.05 mg/kg) and predicted human half-life (t1/2 ∼ 5 days).

HY-137270

16,16-Dimethyl PGA2 16,16-Dimethyl prostaglandin A2; Di-M-PGA2	Endogenous Metabolite	Endocrinology Cancer
16,16-Dimethyl PGA2 is an orally active prostaglandin analog with a prolonged in vivo half-life. 16,16-Dimethyl PGA2 can be used to study hypertension .

HY-135842

Aspoxicillin	Bacterial Antibiotic	Infection
Aspoxicillin is a broad-spectrum antimicrobial agent against 68 isolates of Actinobacillus pleuropneumoniae with an MIC₉₀ value of <= 0.05 μg/ml. Aspoxicillin has a long half-life in mouse serum of 55 minutes .

HY-148571

TP0597850

MMP Inflammation/Immunology Cancer

TP0597850 is a selective inhibitor of MMP2 (IC₅₀=0.22 nM). TP0597850 has a long MMP2 dissociation half-life (t_1/2=265 min) .

TP0597850	MMP	Inflammation/Immunology Cancer
TP0597850 is a selective inhibitor of MMP2 (IC₅₀=0.22 nM). TP0597850 has a long MMP2 dissociation half-life (t_1/2=265 min) .

HY-14834

Budiodarone ATI-2042	Potassium Channel Sodium Channel Calcium Channel	Cardiovascular Disease
Budiodarone (ATI-2042) is an analogue of Amiodarone (HY-14187) with a half-life of 7 h. Budiodarone inhibits sodium, potassium, and calcium ion channels. Budiodarone is an antiarrhythmic agent and can be used for the research of atrial fibrillation .

HY-135226

PROLI NONOate	Others	Others
PROLI NONOate is a NO donor. It spontaneously dissociates in a pH-dependent, first-order process with a half-life of 1.8 seconds at 37°C (pH 7.4) to liberate 2 moles of NO per mole of parent compound.

HY-B1300A

Cefonicid	Others	Others
Pharmacokinetic studies of Cefonicid have shown that high blood concentrations can be achieved rapidly after intravenous and intramuscular injection, and that concomitant use of albendazole prolongs its half-life in the body and reduces the rate of renal excretion .

HY-118561

Bermoprofen AD-1590	Others	Inflammation/Immunology
Bermoprofen (AD-1590) is an orally active non-steroidal anti-inflammatory agent. Bermoprofen has potent antipyretic activities with a short biological half-life. Bermoprofen is a potent antagonist of LPS-induced fever in rabbits .

HY-125301

Thymoctonan	Others	Inflammation/Immunology
Thymoctonan (THF-γ2) is the immunomodulatory octapeptide, thymic humoral factor γ2. Thymoctonan has the half-life less than 6 min at 37 °C in blood from human, rat and mouse .

HY-W394903

GS-829845	JAK Drug Metabolite	Cancer
GS-829845 is a major, active metabolite of Filgotinib (HY-18300). GS-829845 is a JAK1 preferential inhibitor but is approximately 10-fold less potent than the parent and with a longer half-life .

HY-P99671

Isecarosmab M-6495	ADAMTS	Inflammation/Immunology
Isecarosmab (M-6495) is an anti-ADAMTS monoclonal antibody (mAb) with a K_D value of 3.65 pM. Isecarosmab has chondroprotective and anti-inflammatory activities. Isecarosmab can bind albumin to extend plasma half-life .

HY-N4009

Iriflophenone 2-O-α-rhamnoside	Others	Others
Iriflophenone 2-O-α-rhamnoside can be isolated from the leaves of Aquilaria sinensis. Iriflophenone 2-O-α-rhamnoside has a half-life value of 2.44 min in rats at the administration of 25 mg/kg .

HY-163505

Anti-MRSA agent 11	Bacterial	Others
Anti-MRSA agent 11 suppresses fluoroquinolone-sensitive strain USA500 and -resistant MRSA isolate Mu50 (MIC =0.39 μg/mL). Anti-MRSA agent 11 displayes favorable in vivo half-life and safety profiles .

HY-163438

BKIDC-1553	Angiotensin-converting Enzyme (ACE)	Cancer
BKIDC-1553 is an orally active antiglycolytic agent and a bumped kinase inhibitor derived compound with a predicted ~17 h half-life in human. BKIDC-1553 inhibits CYP2C8 and Angiotensin Converting Enzyme and can be used for cancer research .

HY-100607A

Landiolol hydrochloride ONO1101 hydrochloride	Adrenergic Receptor	Cardiovascular Disease Endocrinology
Landiolol hydrochloride (ONO1101 hydrochloride) is a highly beta1 selective ultra-short acting beta-blocker (β1/β2 selectivity = 255:1, a half-life of 4 min)， acts as an adrenoceptor antagonist .

HY-P99350

Gresonitamab AMG 910; Anti-Human CD3xClaudin18 2	CD3	Cancer
Gresonitamab (AMG 910) is a half-life extended (HLE) bispecific T-cell engager (BiTE) antibody targets CD3-positive T cells and CLDN18.2-expressing tumor cells. Gresonitamab can be used for the research of adenocarcinoma .

HY-N7122

Thymopentin	Endogenous Metabolite	Inflammation/Immunology Cancer
Thymopentin is a biologically active peptide secreted mainly by the epithelial cells of thymic cortex and medulla. Thymopentin is an effective immunomodulatory agent with a short plasma half-life of 30 seconds. Thymopentin enhances the generation of T-cell lineage derived from human embryonic stem cells (hESCs) .

HY-N7122A

Thymopentin acetate	Endogenous Metabolite	Inflammation/Immunology Cancer
Thymopentin acetate is a biologically active peptide secreted mainly by the epithelial cells of thymic cortex and medulla. Thymopentin acetate is an effective immunomodulatory agent with a short plasma half-life of 30 seconds. Thymopentin acetate enhances the generation of T-cell lineage derived from human embryonic stem cells (hESCs) .

HY-124713

ML372	DNA/RNA Synthesis	Neurological Disease
ML372 inhibits survival motor neuron (SMN) protein ubiquitination, increases SMN protein stability without affecting mRNA expression. ML372 improves spinal muscular atrophy (SMA) in mice. ML372 is brain penetrant and has a reasonable exposure and half-life in vivo .

HY-P99756

Nirsevimab MEDI8897	RSV	Infection
Nirsevimab (MEDI8897) is a recombinant human respiratory syncytial virus (RSV) monoclonal antibody with modified Fc region, which can prolong its half-life. Nirsevimab has an affinity for RSV-B with an K_d value of 1.5 nM. Nirsevimab can be used for RSV research .

HY-156188

AChE-IN-41	Others	Others
AChE-IN-41 (Compound 2) is a compound of the Galantamine Memantine hybrid. AChE-IN-41 has the inhibition ability of cholinesterase. AChE-IN-41 shows higher plasma stability and comparable microsomal stability in vitro, while showing lower half-life and faster clearance in vivo .

HY-135842R

Aspoxicillin (Standard)	Bacterial Antibiotic	Infection
Aspoxicillin (Standard) is the analytical standard of Aspoxicillin. This product is intended for research and analytical applications. Aspoxicillin is a broad-spectrum antimicrobial agent against 68 isolates of Actinobacillus pleuropneumoniae with an MIC₉₀ value of <= 0.05 μg/ml. Aspoxicillin has a long half-life in mouse serum of 55 minutes .

HY-P99930

Efruxifermin	FGFR	Metabolic Disease
Efruxifermin is an Fc-FGF21 fusion protein (human IgG1 Fc domain linked to a modified human FGF21). Efruxifermin has prolonged half-life and enhanced receptor affinity compared with native human FGF21. Efruxifermin can be used for the research of non-alcoholic steatohepatitis .

HY-P10019

Pegsebrenatide NLY01	GCGR	Neurological Disease
Pegsebrenatide (NLY01) is a long-acting GLP-1R agonist. Pegsebrenatide has an extended half-life and favorable blood-brain barrier penetration. Pegsebrenatide can block A1 astrocyte transformation, reducing dopaminergic cell death, and improving motor symptoms in mouse models of PD .

HY-14466

GW 848687X	Prostaglandin Receptor	Endocrinology
GW 848687X is a selective, orally active prostaglandin EP1 receptor antagonist for the inhibition of inflammatory pain. The oral bioavailability of GW 848687X was 54% in rats and 53% in dogs. GW 848687X has a half-life of 2 hours and has inhibitory potential for both acute and chronic pain .

HY-W739302

Sodium Oxyhyponitrite Sodium α-oxyhyponitrite	Others	Others
Sodium Oxyhyponitrite Angeli (Angeli) is a nitroxyl (NO-) donor, but under certain conditions NO release has also been observed. Sodium Oxyhyponitrite Angeli spontaneously dissociates in a pH-dependent first-order process with a half-life of 2.3 minutes at 37°C (pH 7.4), releasing 0.54 mol NO per mole.

HY-B1118S

Secnidazole-d6 RP-14539-d₆; PM-185184-d₆	Parasite Antibiotic	Infection
Secnidazole-d₆ is the deuterium labeled Secnidazole. Secnidazole (RP-14539;PM-185184) is an orally active azole antibiotic with a longer half-life than metronidazole (HY-B0318). Secnidazole is against the vaginosis-associated bacteria and has the potential for bacterial vaginosis research[1].

HY-100658

Didesmethyl cariprazine	5-HT Receptor Dopamine Receptor	Neurological Disease
Didesmethyl cariprazine is a metabolite of Cariprazine and acts as the predominant circulating active moiety. Didesmethyl cariprazine has a long half-life of 1-3 weeks. Cariprazine is a antipsychotic agent candidate that exhibits high affinity for the D₃ and D₂ receptors, and moderate affinity for the 5-HT_1A receptor .

HY-155507

c-Myc inhibitor 11	c-Myc	Cancer
c-Myc inhibitor 11 (Compound 67e) is a c-MYC inhibitor (pEC₅₀: 6.4). c-Myc inhibitor 11 has high clearance levels, moderate volume of distribution and short half-life in rat pharmacokinetic assay. c-Myc inhibitor 11 can be used for cancer research .

HY-162351

EBP-IN-1	Others	Metabolic Disease
EBP-IN-1 (compound 11) is an inhibitor of emopamil-binding protein (EBP), a sterol isomerase in the cholesterol biosynthetic pathway. EBP-IN-1 has a long half-life in rodents and has good metabolic turnover and brain penetration properties. EBP-IN-1 enhances oligodendrocyte formation in human cortical organoids .

HY-P99562

Tidutamab XmAb-18087	CD3	Cancer
Tidutamab (XmAb-18087) is a humanized and affinity-optimized bispecific antibody (bsAb) targeting SSTR2 binding domain and T-cell binding domain (CD3). Tidutamab possesses a full Fc domain to maintain long serum half-life.Tidutamab eliminates SSTR+ tumor cells by stimulating redirected T cellmediated cytotoxicity (RTcC) .

HY-121246

Fluorofenidone AKF-PD	PI3K Akt	Inflammation/Immunology
Fluorofenidone (AKF-PD), an analogue of AMR69, shows equivalent antifibrotic activity, lower toxicity and longer half-life. Fluorofenidone (AKF-PD) attenuates the progression of renal interstitial fibrosis partly by suppressing NADPH oxidase and extracellular matrix (ECM) deposition via the PI3K/Akt signalling pathway .

HY-100607AR

Landiolol hydrochloride (Standard)	Adrenergic Receptor	Cardiovascular Disease Endocrinology
Landiolol (hydrochloride) (Standard) is the analytical standard of Landiolol (hydrochloride). This product is intended for research and analytical applications. Landiolol hydrochloride (ONO1101 hydrochloride) is a highly beta1 selective ultra-short acting beta-blocker (β1/β2 selectivity = 255:1, a half-life of 4 min)， acts as an adrenoceptor antagonist .

HY-17421

Tenatoprazole TU-199	Proton Pump	Infection Inflammation/Immunology
Tenatoprazole (TU-199) is an orally active imidazopyridine-based proton pump inhibitor with a prolonged plasma half-life. Tenatoprazole inhibits hog gastric H ⁺/K ⁺-ATPase activity with an IC₅₀ of 6.2 μM. Tenatoprazole blocks the interaction of ubiquitin with the ESCRT-1 factor Tsg101, inhibits production of several enveloped viruses, including EBV .

HY-B1118S1

Secnidazole-13C2, 15N2 RP-14539-¹³C₂, ¹⁵N₂; PM-185184-¹³C₂, ¹⁵N₂	Isotope-Labeled Compounds Parasite Antibiotic	Infection
Secnidazole- ¹³C₂, ¹⁵N₂ is the ¹³C₂, ¹⁵N₂ labeled Secnidazole. Secnidazole (RP-14539;PM-185184) is an orally active azole antibiotic with a longer half-life than metronidazole (HY-B0318). Secnidazole is against the vaginosis-associated bacteria and has the potential for bacterial vaginosis research.

HY-149014

OX2R-IN-1	Orexin Receptor (OX Receptor)	Neurological Disease
OX₂R-IN-1 (compound 15) is a low cytotoxicity profile OX₂R-IN-1 antagonist (a potential OX2R binder) with an IC₅₀ value of 484 μM. OX₂R-IN-1 (compound 15) can cross the BBB into the brain with a short half-life .

Cat. No.	Product Name	Target	Research Area

HY-N7122

Thymopentin	Endogenous Metabolite	Inflammation/Immunology Cancer
Thymopentin is a biologically active peptide secreted mainly by the epithelial cells of thymic cortex and medulla. Thymopentin is an effective immunomodulatory agent with a short plasma half-life of 30 seconds. Thymopentin enhances the generation of T-cell lineage derived from human embryonic stem cells (hESCs) .

HY-N7122A

Thymopentin acetate	Endogenous Metabolite	Inflammation/Immunology Cancer
Thymopentin acetate is a biologically active peptide secreted mainly by the epithelial cells of thymic cortex and medulla. Thymopentin acetate is an effective immunomodulatory agent with a short plasma half-life of 30 seconds. Thymopentin acetate enhances the generation of T-cell lineage derived from human embryonic stem cells (hESCs) .

HY-P10274

CM05

Peptides Inflammation/Immunology

CM05 is a bromo-fatty acid. CM05 can be used to modify ornithodoros moubata complement inhibitor (OmCI) and extend the half-life of OmCI .

HY-P10019

Pegsebrenatide NLY01	GCGR	Neurological Disease
Pegsebrenatide (NLY01) is a long-acting GLP-1R agonist. Pegsebrenatide has an extended half-life and favorable blood-brain barrier penetration. Pegsebrenatide can block A1 astrocyte transformation, reducing dopaminergic cell death, and improving motor symptoms in mouse models of PD .

HY-P1838

Proadrenomedullin (45-92), human	Peptides	Cardiovascular Disease
Proadrenomedullin (45-92), human, a mid-regional fragment of proadrenomedullin (MR-proADM), comprises amino acids 45–92 of pre-proADM. Proadrenomedullin (45-92), human has a longer half-life, is relatively stable and is produced in equimolar amounts to adrenomedullin (ADM), making it a surrogate for plasma levels of ADM gene products .

HY-P3347

NH2-c[X-R-L-S-X]-K-G-P-(D-2Nal)	Apelin Receptor (APJ)	Cardiovascular Disease
NH2-c[X-R-L-S-X]-K-G-P-(D-2Nal) (compound 40), a macrocyclic analogue of Ape13, is a potent APJ agonist (K_i=5.7 nM). NH2-c[X-R-L-S-X]-K-G-P-(D-2Nal) exhibits a favorable Gα12-biased signaling and an increased in vivo half-life .

Cat. No.	Product Name	Target	Research Area

HY-P99671

Isecarosmab M-6495	ADAMTS	Inflammation/Immunology
Isecarosmab (M-6495) is an anti-ADAMTS monoclonal antibody (mAb) with a K_D value of 3.65 pM. Isecarosmab has chondroprotective and anti-inflammatory activities. Isecarosmab can bind albumin to extend plasma half-life .

HY-P99350

Gresonitamab AMG 910; Anti-Human CD3xClaudin18 2	CD3	Cancer
Gresonitamab (AMG 910) is a half-life extended (HLE) bispecific T-cell engager (BiTE) antibody targets CD3-positive T cells and CLDN18.2-expressing tumor cells. Gresonitamab can be used for the research of adenocarcinoma .

HY-P99756

Nirsevimab MEDI8897	RSV	Infection
Nirsevimab (MEDI8897) is a recombinant human respiratory syncytial virus (RSV) monoclonal antibody with modified Fc region, which can prolong its half-life. Nirsevimab has an affinity for RSV-B with an K_d value of 1.5 nM. Nirsevimab can be used for RSV research .

HY-P99930

Efruxifermin	FGFR	Metabolic Disease
Efruxifermin is an Fc-FGF21 fusion protein (human IgG1 Fc domain linked to a modified human FGF21). Efruxifermin has prolonged half-life and enhanced receptor affinity compared with native human FGF21. Efruxifermin can be used for the research of non-alcoholic steatohepatitis .

HY-P99478

Bifarcept

IFNAR Inflammation/Immunology

Bifarcept is a recombinant antibody of interferon receptor type I (IFN-RI). Bifarcept can bind IFN-β and prolong its serum half-life .

HY-P99562

Tidutamab XmAb-18087	CD3	Cancer
Tidutamab (XmAb-18087) is a humanized and affinity-optimized bispecific antibody (bsAb) targeting SSTR2 binding domain and T-cell binding domain (CD3). Tidutamab possesses a full Fc domain to maintain long serum half-life.Tidutamab eliminates SSTR+ tumor cells by stimulating redirected T cellmediated cytotoxicity (RTcC) .

HY-P99814

Pavurutamab AMG-701	CD3	Inflammation/Immunology Cancer
Pavurutamab (AMG-701) is a bispecific T cell engager molecule that anti-CD3 and anti-B cell maturation antigens (BCMA). Pavurutamab has an extended half-life based on Pacanalotamab (HY-P99798). The Fc of Pavurutamab is coupled to molecules to improve pharmacokinetic parameters. Pavurutamab has potential applications in immune regulation and multiple myeloma (MM) .

HY-P99340

Sotrovimab 1 Publications Verification VIR 7831	SARS-CoV	Infection
Sotrovimab (VIR 7831) is a human IgG1κ pan-sarbecovirus monoclonal antibody (mAb), neutralizes SARS-CoV-2, SARS-CoV-1, and multiple other sarbecoviruses. Sotrovimab is developed based on S309, exhibits a long half-life and great bioavailability in the respiratory mucosa. Sotrovimab could result in immune-mediated viral clearance and prevent progression of Covid-19 early in the course of disease .

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-134636

PAPA NONOate	Structural Classification Alkaloids Classification of Application Fields Other Alkaloids Source classification Endogenous metabolite Disease Research Fields Endocrinology	Endogenous Metabolite
PAPA NONOate is a NO donor with a NO release half-life of 77 min (22-25°C). PAPA NONOate may represent a potential research for impaired wound healing in diabetes by increasing the rate of collagen synthesis at the wound site .

HY-N7122

Thymopentin	Structural Classification Monophenols Classification of Application Fields Ketones, Aldehydes, Acids Source classification Phenols Endogenous metabolite Disease Research Fields Cancer	Endogenous Metabolite
Thymopentin is a biologically active peptide secreted mainly by the epithelial cells of thymic cortex and medulla. Thymopentin is an effective immunomodulatory agent with a short plasma half-life of 30 seconds. Thymopentin enhances the generation of T-cell lineage derived from human embryonic stem cells (hESCs) .

HY-N7122A

Thymopentin acetate	Monophenols Classification of Application Fields Ketones, Aldehydes, Acids Source classification Phenols Endogenous metabolite Disease Research Fields Inflammation/Immunology	Endogenous Metabolite
Thymopentin acetate is a biologically active peptide secreted mainly by the epithelial cells of thymic cortex and medulla. Thymopentin acetate is an effective immunomodulatory agent with a short plasma half-life of 30 seconds. Thymopentin acetate enhances the generation of T-cell lineage derived from human embryonic stem cells (hESCs) .

HY-N4009

Iriflophenone 2-O-α-rhamnoside	Structural Classification Thymelaeaceae Source classification Phenols Polyphenols Plants Aquilaria sinensis (Lour.) Spreng.	Others
Iriflophenone 2-O-α-rhamnoside can be isolated from the leaves of Aquilaria sinensis. Iriflophenone 2-O-α-rhamnoside has a half-life value of 2.44 min in rats at the administration of 25 mg/kg .

Cat. No.	Product Name	Chemical Structure

HY-B1118S

Secnidazole-d6
Secnidazole-d₆ is the deuterium labeled Secnidazole. Secnidazole (RP-14539;PM-185184) is an orally active azole antibiotic with a longer half-life than metronidazole (HY-B0318). Secnidazole is against the vaginosis-associated bacteria and has the potential for bacterial vaginosis research[1].

HY-B1118S1

Secnidazole-13C2, 15N2
Secnidazole- ¹³C₂, ¹⁵N₂ is the ¹³C₂, ¹⁵N₂ labeled Secnidazole. Secnidazole (RP-14539;PM-185184) is an orally active azole antibiotic with a longer half-life than metronidazole (HY-B0318). Secnidazole is against the vaginosis-associated bacteria and has the potential for bacterial vaginosis research.

HY-121246S

Fluorofenidone-d3
Fluorofenidone-d₃ is deuterium labeled Fluorofenidone. Fluorofenidone (AKF-PD), an analogue of AMR69, shows equivalent antifibrotic activity, lower toxicity and longer half-life. Fluorofenidone (AKF-PD) attenuates the progression of renal interstitial fibrosis partly by suppressing NADPH oxidase and extracellular matrix (ECM) deposition via the PI3K/Akt signalling pathway[1][2].

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

half-life

Inhibitors & Agonists

Fluorescent Dye

Peptides

Inhibitory Antibodies

NaturalProducts

Isotope-Labeled Compounds

Natural
Products